1Nisssen SE. High-dose statins in acute coronary syndromes. Not just lipid levels JAMA, 2004,1292,1365-1367.
2Henst protection study, collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastation in 20536 high-risk individuals: a randomized placebo-contrdled trial. Lancet, 2002,360:7-22.
3expert panel on Detection. Evaluation and Treatment of High Blood cholesterolin Adults. Excutive Summary of the Third peport of the National cholesterol Education Program (IVCEP) Expert pane/on Detection, Evaluation,and Treatment of High Blood cholesterol in Aolult (atp Ⅲ).JAM ,2001,19:2486-2497.
4Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastain on early recurrent ischemic events in acute ccoronary syndromes:the MIRACLE study. Arandomized controlledtrial. JAMA, 2001,285: 1711-1718.
5cannon CP,I Braunwald E, Mclade C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med,2004,350 : 1495-1504.
6Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease, application to clinical and public health practice:a statement for healthcare profession from the centers for disease control and prevention and the American Heart Associalion. Circulation,2003,107:499-512.
5Mcpherson R,Kavaslar N.Statins for primary prevention of coronary artery disease[J].Lancet,2007,369(6):1078.
6Tanaka N,Katayama Y,Katsumata T,et al.Effects of long -term administration of HMG-CoA reductase inhibitor,atorvastatin,on stroke events and local cerebral blood flow in strokeprone spontaneously hypertensive rats[J].Brain Res,2007,1169(1):125.
7Gershlick AH,Belder M,Chambers J,et al.Role of noninvasive imaging in the management of coronary artery disease:an assessment of likely change over the next 10 years.A report from the British Cardiovascular Society Working Group[J].Heart,2007,93(4):423.
